Epigral, one of India’s leading integrated chemical manufacturers, announced its financial results for the quarter ended 30 September 2025. The company reported revenue of Rs 5.89 billion, compared to Rs 6.32 billion in Q2 FY25. PAT for the quarter stood at Rs 510 million, against Rs 810 million recorded in the corresponding period last year.

Commenting on the performance, Maulik Patel, Chairman & Managing Director, Epigral, said, “This quarter saw lower revenue due to reduced sales volumes and softer realizations in a few product categories. The volume decline was primarily driven by the extended monsoon season, which is an off-season for some of our products. Overall plant utilization stood at 75 per cent for H1 FY26, and we expect improvement in the second half as the monsoon has ended and planned maintenance activities are complete.”

He added that capacity expansion projects for CPVC, Epichlorohydrin, and the Wind–Solar Hybrid power plant are progressing as per schedule and are expected to be commissioned within the committed timelines. These projects are set to support growth from FY27 onwards. Epigral is also advancing discussions on additional new projects, which will be announced upon final board approval.

“We remain committed to scalable and profitable growth, optimizing capital allocation, strengthening our integration, and delivering long-term value for all stakeholders,” Patel said.

Epigral expects a stronger second half driven by improved plant utilization, stabilized demand, and the completion of maintenance activities.